James D Doecke

Dr. James D Doecke

CSIRO Health and Biosecurity, Clayton South, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JBJessica Biesiekierski
Jessica Biesiekierski
ENEvan D Newnham
Evan D Newnham
PIPeter M Irving
Peter M Irving
JBJacqueline S Barrett
Jacqueline S Barrett
MHMelissa Haines
Melissa Haines
PGPeter R Gibson
Peter R Gibson
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)

28 October 2014 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
Lesley ChengLesley Cheng
Lesley Cheng
JDJames D Doecke
James D Doecke
RSR A Sharples
R A Sharples
VVV L Villemagne
V L Villemagne
CFC J Fowler
C J Fowler
AHAndrew Hill
Andrew Hill

1 October 2012 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
JDJames D Doecke
James D Doecke
Alzheimer disease (AD) is the most common form of dementia, affecting more than 27 million persons worldwide and predicted to affect 86 million people by the year 2050.1 The disease is characterized morphologically by an overall loss of synapses and neurons and an overall reduction in brain volume.2 The identification of peripheral biomarkers of the disease process leading to an effective and early diagnostic test for AD would allow for presymptomatic detection of disease and would be valuable for monitoring the efficacy of disease interventions during clinical trials.

14 June 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
RFRicardo C. Ferreira
Ricardo C. Ferreira
HGHui Guo
Hui Guo
RCRichard M.R. Coulson
Richard M.R. Coulson
DSDeborah J. Smyth
Deborah J. Smyth
MPMarcin L. Pekalski
Marcin L. Pekalski
AZAnette-G. Ziegler
Anette-G. Ziegler
Diagnosis of the autoimmune disease type 1 diabetes (T1D) is preceded by the appearance of circulating autoantibodies to pancreatic islets. However, almost nothing is known about events leading to this islet autoimmunity. Previous epidemiological and genetic data have associated viral infections and antiviral type I interferon (IFN) immune response genes with T1D. Here, we first used DNA microarray analysis to identify IFN-β–inducible genes in vitro and then used this set of genes to define an IFN-inducible transcriptional signature in peripheral blood mononuclear cells from a group of active systemic lupus erythematosus patients (n = 25). Using this predefined set of 225 IFN signature genes, we investigated the expression of the signature in cohorts of healthy controls (n = 87), patients with T1D (n = 64), and a large longitudinal birth cohort of children genetically predisposed to T1D (n = 109; 454 microarrayed samples). Expression of the IFN signature was increased in genetically predisposed children before the development of autoantibodies (P = 0.0012) but not in patients with established T1D. Upregulation of IFN-inducible genes was transient, temporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and marked by increased expression of SIGLEC-1 (CD169), a lectin-like receptor expressed on CD14+ monocytes. DNA variation in IFN-inducible genes altered T1D risk (P = 0.007), as exemplified by IFIH1, one of the genes in our IFN signature for which increased expression is a known risk factor for disease. These findings identify transient increased expression of type I IFN genes in preclinical diabetes as a risk factor for autoimmunity in children with a genetic predisposition to T1D.

27 February 2008 in Gut
Verified
Journal Article
Open access
PDF file
LSL A Simms
L A Simms
JDJames D Doecke
James D Doecke
MWM D Walsh
M D Walsh
NHN Huang
N Huang
EFE V Fowler
E V Fowler
GRG L Radford-Smith
G L Radford-Smith
Background and aims: Reduced ileal Paneth cell α-defensin expression has been reported to be associated with Crohn’s disease, especially in patients carrying NOD2 mutations. The aim of this study was to independently assess whether NOD2, α-defensins and Crohn’s disease are linked. Methods: Using quantitative real-time polymerase chain reaction (RT-PCR), we measured the mRNA expression levels of key Paneth cell antimicrobial peptides (DEFA5, DEFA6, LYZ, PLA2G2A), inflammatory cytokines [interkelukin 6 (IL6) and IL8], and a marker of epithelial cell content, villin (VIL1) in 106 samples from both affected ileum (inflamed Crohn’s disease cases, n = 44) and unaffected ileum (non-inflamed; Crohn’s disease cases, n = 51 and controls, n = 11). Anti-human defensin 5 (HD-5) and haematoxylin/eosin immunohistochemical staining was performed on parallel sections from NOD2 wild-type and NOD2 mutant ileal Crohn’s disease tissue. Results: In Crohn’s disease patients, DEFA5 and DEFA6 mRNA expression levels were 1.9- and 2.2-fold lower, respectively, in histologically confirmed inflamed ileal mucosa after adjustment for confounders (DEFA5, p<0.001; DEFA6, p = 0.001). In contrast to previous studies, we found no significant association between α-defensin expression and NOD2 genotype. HD-5 protein data supports these RNA findings. The reduction in HD-5 protein expression appears due to surface epithelial cell loss and reduced Paneth cell numbers as a consequence of tissue damage. Conclusions: Reduction in α-defensin expression is independent of NOD2 status and is due to loss of surface epithelium as a consequence of inflammatory changes rather than being the inciting event prior to inflammation in ileal Crohn’s disease.

1 August 2014 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
ARAlan Rembach
Alan Rembach
AWAndrew D Watt
Andrew D Watt
WWWilliam J Wilson
William J Wilson
SRStephanie Rainey-Smith
Stephanie Rainey-Smith
KEKathryn A Ellis
Kathryn A Ellis
AGAIBL Research Group
AIBL Research Group